Expressions of Matrix Metalloproteinase-7 and -9 and their Prognostic Significances in Rectal Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The matrix metalloproteinases (MMPs) are a family of proteolytic enzymes. MMPs are known to be involved in tumor invasion, and several have been implicated in tumor prognosis. The aim of this study was to evaluate the prognostic significances of the expressions of MMP-7 and -9 in rectal cancer. Materials and Methods: The tumor tissues of 87 patients with stage II or III rectal carcinoma that underwent potentially curative resection followed by postoperative adjuvant chemoradiation and 5-fluorouracil based chemotherapy, were investigated immunohistochemically using monoclonal antibodies against MMP-7 and MMP-9. Clinical information, including tumor grades, carcinoembryonic antigen (CEA) levels, and disease-free survival and overall survival were evaluated with respect to the expressions of MMP-7 and -9. Results: Median follow-up duration was 53.2 months, and median patient age was 55±11 years (range 32∼75).MMP-7 expression in tumor tissue was found to be significantly correlated with the presence of nodal metastasis (p=0.029), whilst MMP-9 expression correlated with depth of tumor invasion (p=0.019). No relationships were found between the expressions of MMP-7 or -9 and age, sex, tumor size, tumor grade, or CEA level. Univariate analysis showed that MMP-7 expression was associated with poor 5-year overall survival (12.8 months vs. 65.3 months, p=0.0405). Multivariate analysis confirmed that MMP-7 was independently associated with an adverse outcome (Relative risk: 1.415, p=0.027). However, MMP-9 expression was not found to be related to clinical outcome. Conclusion: MMP-7 expression in tumor tissue is associated with lymph node metastasis and a poor 5-year overall survival in rectal cancer patients.
Abstract
Purpose: The matrix metalloproteinases (MMPs) are a family of proteolytic enzymes. MMPs are known to be involved in tumor invasion, and several have been implicated in tumor prognosis. The aim of this study was to evaluate the prognostic significances of the expressions of MMP-7 and -9 in rectal cancer. Materials and Methods: The tumor tissues of 87 patients with stage II or III rectal carcinoma that underwent potentially curative resection followed by postoperative adjuvant chemoradiation and 5-fluorouracil based chemotherapy, were investigated immunohistochemically using monoclonal antibodies against MMP-7 and MMP-9. Clinical information, including tumor grades, carcinoembryonic antigen (CEA) levels, and disease-free survival and overall survival were evaluated with respect to the expressions of MMP-7 and -9. Results: Median follow-up duration was 53.2 months, and median patient age was 55±11 years (range 32∼75).MMP-7 expression in tumor tissue was found to be significantly correlated with the presence of nodal metastasis (p=0.029), whilst MMP-9 expression correlated with depth of tumor invasion (p=0.019). No relationships were found between the expressions of MMP-7 or -9 and age, sex, tumor size, tumor grade, or CEA level. Univariate analysis showed that MMP-7 expression was associated with poor 5-year overall survival (12.8 months vs. 65.3 months, p=0.0405). Multivariate analysis confirmed that MMP-7 was independently associated with an adverse outcome (Relative risk: 1.415, p=0.027). However, MMP-9 expression was not found to be related to clinical outcome. Conclusion: MMP-7 expression in tumor tissue is associated with lymph node metastasis and a poor 5-year overall survival in rectal cancer patients.
참고문헌 (21)
- "2001 Annual Reportof the Korea Central Cancer Registry: based data from 134hospitals.", 36, pp.19~30 (2004)
- "Effective surgical adjuvant therapy forhigh-risk rectal carcinoma", 324, pp.709~15 (1991)
- "radiotherapyfor rectal cancer: a systematic overview of 8,507 patients from22 randomised trials", 358, pp.1291~304 (2001)
- "Improving adjuvant therapyfor rectal cancer by combining protracted-infusion 5-FU withradiation therapy after curative surgery", 331, pp.502~7 (1994)
- "Assessment of biomarkers in paired primary and recurrentcolorectal adenocarcinomas", 45, pp.1167~73 (1999)
- "Prognostic value of proliferation,apoptosis, defective DNA mismatch repair, and p53 overexpressionin patients with resected Dukes' B2 or C colon cancer:a North Central Cancer Treatment Group Study", 22, pp.1572~82 (2004)
- "Tumor and stromal expressionof matrix metalloproteinases and their role in tumor progression", 14, pp.234~45 (1995)
- "Matrix metalloproteinases:multifunctionalcontributors to tumor progression", 6, pp.149~56 (2000)
- "Purification and characterization of extracellular matrix-degradingmetalloproteinase secreted from humanrectal carcinoma cell line", pp.7758~1 64 (1990)
- "Contribution of matrilysin (MMP-7) to the metastatic pathwayof human colorectal cancers.", 45, pp.252~8 (1999)
- "Role of matrix metalloproteinases (MMPs)in colorectal cancer", 23, pp.101~17 (2004)
- "Metalloproteinases and cancerinvasion", 1, pp.99~106 (1990)
- "Prediction ofcolorectal cancer relapse and survival via tissue RNA levelsof matrix metalloproteinase-9", 14, pp.3133~40 (1996)
- "Activity and cellular origin of gelatinases in patientswith colon and rectal carcinoma differential activity of matrixmetalloproteinase-9", 92, pp.2680~91 (2001)
- "Matrix metalloproteinasesin colorectal cancer: is it worth talking about?", 23, pp.119~35 (2004)
- "Overexpression of matrix metalloproteinase-7 mRNAin human colon carcinomas", 75, pp.1516~9 (1995)
- "Clinicopathologic and prognostic significance of matrilysinexpression at the invasive front in human colorectalcancers", 95, pp.290~4 (2001)
- "The role of gelatinasesin colorectal cancer progression and metastasis", 1705, pp.69~89 (2004)
- "Spectrum of matrixmetalloproteinase expression in primary and metastatic coloncancer relationship to the tissue inhibitors of metalloproteinasesand membrane type-1-matrix metalloproteinase", 84, pp.1664~70 (2001)
- "Host expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in normalcolon tissue affects metastatic potential of colorectal cancer", 42, pp.393~7 (1999)
- "Matrix metalloproteinaseinhibitors and cancer: trials and tribulations.", 295, pp.2387~92 (2002)